Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study

31 Aug 2016

Abstract excerpt

Several candidate vaccines against Shigella spp. are in development, but the lack of a clear correlate of protection from challenge with the induction of adequate immune responses among the youngest age groups in the developing world has hampered Shigella vaccine development over the past several decades. Bioconjugation technology, exploited here for an Shigella flexneri 2a candidate vaccine, offers a novel and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clostridium difficile and Clostridium perfringens research
Share to Escherichia coli research studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Viral gastroenteritis research and epidemiology

Source

Identifiers

PMID: 27581434
DOI: 10.1128/cvi.00224-16

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I StudyPMID 27581434Read ↗

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionSemantic proximity Read ↗

Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult SubjectsSemantic proximity Read ↗

A next-generation GMMA-based vaccine candidate to fight shigellosisSemantic proximity Read ↗

The Shigella Vaccines PipelineSemantic proximity Read ↗

Status of vaccine research and development for ShigellaSemantic proximity Read ↗

Towards establishing correlates of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) candidate vaccine (1790GAHB).Semantic proximity Read ↗

Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccineSemantic proximity Read ↗

Outer membrane vesicles derived from <i>Salmonella</i> Typhimurium can deliver <i>Shigella flexneri</i> 2a O-polysaccharide antigen to prevent lethal pulmonary infection in miceSemantic proximity Read ↗

BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in miceSemantic proximity Read ↗

Modular biomaterials vaccine technology protects against multiple pathogens and septic shockSemantic proximity Read ↗

Polymeric epitope-based vaccine induces protective immunity against group A StreptococcusSemantic proximity Read ↗

From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine’s Refinement and EvolutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.